Target Name: RBBP9
NCBI ID: G10741
Review Report on RBBP9 Target / Biomarker Content of Review Report on RBBP9 Target / Biomarker
RBBP9
Other Name(s): retinoma-binding protein 9 | retinoblastoma-binding protein 9 | Retinoma-binding protein 9 | Protein BOG | RBBP-9 | Retinoblastoma-binding protein 9 | B5T-overexpressed gene protein | putative hydrolase RBBP9 | RB binding protein 9, serine hydrolase | Serine hydrolase RBBP9 | RBBP10 | BOG | MGC9236 | Retinoblastoma-binding protein 10 | RBBP-10 | B5T overexpressed gene protein | retinoblastoma-binding protein 10 | RBBP9_HUMAN

Understanding RBBP9: Potential Drug Targets and Biomarkers

Retinoma-binding protein 9 (RBBP9) is a protein that is expressed in a variety of tissues, including the brain, and is known for its role in the development and progression of certain diseases, such as cancer. Despite its importance, little is known about RBBP9, and it has not been extensively studied. However, research into RBBP9 has the potential to uncover new drug targets and biomarkers for a variety of diseases.

One of the main functions of RBBP9 is its role in cell signaling. RBBP9 is a protein that is known to interact with several different signaling pathways, including the TGF-β pathway and the Wnt pathway. These signaling pathways are involved in a wide range of processes in the cell, including cell growth, differentiation, and survival.

Research has shown that RBBP9 is involved in the regulation of cell proliferation and survival. For example, studies have shown that RBBP9 can inhibit the effects of the TGF-β pathway on cell proliferation and can also inhibit the formation of new blood vessels in tumors. These findings suggest that RBBP9 may be a potential drug target for diseases that are characterized by uncontrolled cell growth, such as cancer.

Another function of RBBP9 is its role in the development and progression of certain diseases. For example, studies have shown that RBBP9 is involved in the development of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. These findings suggest that RBBP9 may be a potential biomarker for these diseases and may also be a target for new therapies.

Despite its potential importance, little is known about RBBP9. The lack of information about RBBP9 makes it difficult to study it and determine its true potential as a drug target or biomarker. However, research into RBBP9 has the potential to uncover new insights into the biology of this protein and its role in the development and progression of disease.

In conclusion, RBBP9 is a protein that is expressed in a variety of tissues and is involved in several important functions, including cell signaling and disease development and progression. While more research is needed, the potential for RBBP9 as a drug target or biomarker for a variety of diseases is significant. Further research into RBBP9 and its role in the development and progression of disease may lead to new and exciting discoveries in the future.

Protein Name: RB Binding Protein 9, Serine Hydrolase

Functions: Serine hydrolase whose substrates have not been identified yet (PubMed:19329999, PubMed:20080647). May negatively regulate basal or autocrine TGF-beta signaling by suppressing SMAD2-SMAD3 phosphorylation (PubMed:20080647). May play a role in the transformation process due to its capacity to confer resistance to the growth-inhibitory effects of TGF-beta through interaction with RB1 and the subsequent displacement of E2F1 (PubMed:9697699)

The "RBBP9 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RBBP9 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

RBCK1 | RBFA | RBFOX1 | RBFOX2 | RBFOX3 | RBIS | RBKS | RBL1 | RBL2 | RBM10 | RBM11 | RBM12 | RBM12B | RBM14 | RBM14-RBM4 | RBM15 | RBM15-AS1 | RBM15B | RBM17 | RBM17P1 | RBM18 | RBM19 | RBM20 | RBM22 | RBM22P1 | RBM23 | RBM24 | RBM25 | RBM26 | RBM26-AS1 | RBM27 | RBM28 | RBM3 | RBM33 | RBM34 | RBM38 | RBM39 | RBM4 | RBM41 | RBM42 | RBM43 | RBM43P1 | RBM44 | RBM45 | RBM46 | RBM47 | RBM48 | RBM48P1 | RBM4B | RBM5 | RBM5-AS1 | RBM6 | RBM7 | RBM8A | RBMS1 | RBMS1P1 | RBMS2 | RBMS2P1 | RBMS3 | RBMS3-AS3 | RBMX | RBMX2 | RBMX2P1 | RBMXL1 | RBMXL2 | RBMXL3 | RBMY1A1 | RBMY1B | RBMY1D | RBMY1F | RBMY1J | RBMY2EP | RBMY2FP | RBP1 | RBP2 | RBP3 | RBP4 | RBP5 | RBP7 | RBPJ | RBPJL | RBPJP2 | RBPMS | RBPMS-AS1 | RBPMS2 | RBSN | RBX1 | RC3H1 | RC3H2 | RCAN1 | RCAN2 | RCAN3 | RCAN3AS | RCBTB1 | RCBTB2 | RCC1 | RCC1L | RCC2 | RCCD1 | RCE1